دورية أكاديمية

Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model

التفاصيل البيبلوغرافية
العنوان: Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model
المؤلفون: Ye, Lei, Haider, Husnain Kh., Jiang, Shujia, Ling, Lieng H., Ge, Ruowen, Law, Peter K., Sim, Eugene K.W.
المصدر: European Journal of Heart Failure; Oct2005, Vol. 7 Issue 6, p945-952, 8p
مصطلحات موضوعية: MYOCARDIUM, MYOBLAST transfer therapy, CELLULAR therapy, THERAPEUTICS, HEART diseases, RODENTS, WOUNDS & injuries
مستخلص: Abstract: Background: We hypothesized that combination therapy using human myoblasts and VEGF165 will lead to better prognosis in a failing heart. Methods: Forty-eight female Wistar rats with cryoinjured hearts were randomized into non-treated normal (group-1, n =12), DMEM injected (group-2, n =10), myoblast-transplanted (group-3, n =12) and myoblast–hVEGF165 (group-4, n =14). Ten days after cryoinjury, 200 μl DMEM containing 3×106 cells or without cells was injected into the injured myocardium. Animals were maintained on cyclosporine for 6 weeks post cell transplantation. Heart function was assessed by echocardiography. Animals were sacrificed and hearts were processed for histochemical and immunohistochemical studies. Results: Histological examination showed survival of the donor myoblasts expressing lac-z and hVEGF165 in rat cardiac tissue. Fluorescent immunostaining for vWillebrand Factor-VIII and smooth muscle actin expression at low power microscope (×100) showed significantly higher blood vessel density in group-4 (31.25±1.82; 24.63±0.92) as compared to group-2 (13.29±1.0; p <0.001; 9.71±0.81, p <0.001) and group-3 (16.50±1.43, p <0.001; 14.5±1.34, p <0.001). Echocardiography showed that ejection fraction and fractional shortening of group-3 (93.36±1.52%, p =0.005; 75±3.75%, p =0.024) and group-4 (94.8±1.62%, p =0.003; 76.13±2.15%, p =0.011) significantly improved as compared to group-2 (81.8±3.3%, 55.1±7.18%). Conclusion: Myoblasts carrying of hVEGF165 are potential therapeutic transgene carriers for cardiac repair. [Copyright &y& Elsevier]
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:13889842
DOI:10.1016/j.ejheart.2005.03.012